Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
So low cost! It's worth geting penis vibrator in our Sex Toys Store.
Popular Articles

Novel Compounds May Help Protect Against Respiratory Depression
A paper that appears in the June 2009 issue of Anesthesiology details how AMPAKINE CX717, a Phase II compound created by Irvine, California-based neuroscience company Cortex Pharmaceuticals, demonstrated the rescue of fentanyl-induced respiratory depression and sleep apnea in rats. In this same study, CX717 demonstrated equal efficacy with the opioid antagonist Naloxone, a drug used to counter the effects of opioids on suppression of breathing. CX717 did not, however, interfere with the action of pain-killing opiates. This offers a distinct advantage compared with Naloxone and could provide a novel therapeutic means of treating those patients who are particularly prone to breathing depression with opiates while achieving maximum pain relief.
pharmacy online Dentisti fiume
Gene Therapy Technique Thwarts Cancer By Cutting Off Tumor Blood Supply
University of Florida researchers have come up with a new gene therapy method to disrupt cancer growth by using a synthetic protein to induce blood clotting that cuts off a tumor"s blood and nutrient supply.
News of the day
Lawmakers Seek Price Tag They Can Agree On
"Lawmakers working to overhaul the U.S. health-care system face a pressure-filled July after leaving town this week without resolving the biggest questions dividing Democrats and Republicans," Bloomberg reports. Democrats on the Senate Finance Committee - which observers deem most likely to come up with a passable, bipartisan bill - have been working to reduce the cost of the overhaul to gain Republican support, but had not yet released a proposal. Bloomberg adds: "While the Congressional Budget Office said options under consideration by the committee can keep the cost within Baucus"s goal of $1 trillion over 10 years, how to pay for the plan remains unsettled. So is structuring some kind of government-run competition for insurers. ... "Nothing has been set," Montana Democrat [Max] Baucus told reporters in the Capitol on June 25. The recess offers a chance for "taking stock," he said" (Jensen and Livkin, 6/29).
Diagnostics

Bone Marrow Cell Therapy May Be Beneficial For Patients With Ischemic Heart Disease

The injection of bone marrow cells into the heart of patients with chronic myocardial ischemia (reduced blood flow to some areas of the heart) was associated with modest improvements in blood flow and function of the left ventricle, according to a study in the May 20 issue of JAMA. Bone marrow cell therapy is currently being investigated as a new therapeutic option for patients with ischemic heart disease. Two small-sized studies assessed the effect of this therapy in patients with chronic myocardial ischemia, but with varying results, according to background information in the article. Jan van Ramshorst, M.D., of Leiden University Medical Center, the Netherlands, and colleagues assessed the effect of intramyocardial (within the heart wall) bone marrow cell injection on myocardial perfusion (the flow of blood to the heart muscle) and left ventricular (LV) function in patients with chronic ischemia who were not eligible for conventional treatment. The trial included 50 patients (average age, 64 years; 43 men), who were randomized to receive about 8 injections of either bone marrow cells or placebo solution. At 3-month follow-up, when the two groups were compared, the improvement in summed stress score (a measure of myocardial perfusion) was significantly greater in the bone marrow-cell treated patients as compared with placebo-treated patients. Magnetic resonance imaging indicated that the absolute increase in left ventricular ejection fraction (LVEF; a measure of how well the left ventricle of the heart pumps with each contraction) was significantly larger in bone marrow cell-treated patients. A quality-of-life score increased at 3 and 6 months in bone marrow cell-treated patients, compared with a smaller increase in the placebo group. There was also greater improvement in exercise capacity in the bone marrow cell group. "In summary, the results of this randomized, double-blind, placebo-controlled trial demonstrate that intramyocardial bone marrow cell injection in patients with chronic ischemia is associated with significant improvements in anginal symptoms, myocardial perfusion, and LV function," the authors write. JAMA 2009;301[19]:1997-2004. JAMA


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009